EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

TPS05 - Asthma 2

Friday 31 May, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
D1.86
A 12 months real-life prospective study of lung function in patients with severe eosinophilic asthma undergoing therapy with ics/laba, lama, and anti IL5/5R monoclonal antibody
D1.80
Asthma control, lung function, and quality of life in pediatric patients with severe asthma undergoing biological treatment
D1.79
Benefits of the combination of biologics in the control of a patient with high type 2 profile: a case report
D1.78
Dupilumab Efficacy in Allergic Bronchopulmonary Aspergillosis: a Case Report
D1.75
Effectiveness of low dose mepolizumab in Korean eosinophilic granulomatosis with polyangiitis (EGPA) patients
D1.74
Evaluation of the Pediatric Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
D1.76
Long-Term Efficacy of Mepolizumab at 5 Years in Patients with Severe Asthma
D1.77
Safety of dupilumab in patients with severe asthma: real-life experience
D1.84
Severe asthma in pediatrics and Dupilumab after failure with Omalizumab
D1.81
Successful treatment of severe asthma after switch of biologics. A case report
D1.83
Use of dupilumab in two pregnant women with nasal polyposis and severe persistent asthma: two case reports
D1.73
Use of mepolizumab in a patient with early-onset and difficult-to-control asthma: A case report
D1.82
VEXAS overlapping I-HES. A case report
D1.72
Variables predicting clinical remission among adults with severe asthma treated with biologic agents

Chairs

Speakers